Skip to content
10-Q

Quarterly Report

SPARK THERAPEUTICS, INC.

0001609351-18-000076

← back to feed
Filed
Nov 6, 2018 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2018 · Nov 1, 2018 37.75M sh
Stock Repurchased Q3 2018 · Sep 30, 2018 $3.27M
Stock Repurchased restated Q3 2018 · Sep 30, 2017 $633K
Long Term Debt Q3 2018 · Sep 30, 2018 $47.67M
Long Term Debt Q3 2018 · Dec 31, 2017 $912K
Short Term Debt Q3 2018 · Sep 30, 2018 $3.32M
Short Term Debt Q3 2018 · Dec 31, 2017 $312K
Cash And Equivalents Q3 2018 · Sep 30, 2018 $161.56M
Cash And Equivalents Q3 2018 · Dec 31, 2017 $96.75M
Current Liabilities Q3 2018 · Sep 30, 2018 $59.32M
Current Liabilities Q3 2018 · Dec 31, 2017 $53.69M
Total Liabilities Q3 2018 · Sep 30, 2018 $257.53M
Total Liabilities Q3 2018 · Dec 31, 2017 $103.17M
Current Assets Q3 2018 · Sep 30, 2018 $635.21M
Current Assets Q3 2018 · Dec 31, 2017 $533.17M
Total Assets Q3 2018 · Sep 30, 2018 $807.4M
Total Assets Q3 2018 · Dec 31, 2017 $616.8M
Sga Expense Q3 2018 · Sep 30, 2018 $29.31M
Sga Expense Q3 2018 · Sep 30, 2018 $92.54M
Sga Expense Q3 2018 · Sep 30, 2017 $26.64M
Sga Expense Q3 2018 · Sep 30, 2017 $74.78M
Rd Expense Q3 2018 · Sep 30, 2018 $32.83M
Rd Expense Q3 2018 · Sep 30, 2018 $88.46M
Rd Expense restated Q3 2018 · Sep 30, 2017 $39.34M
Rd Expense restated Q3 2018 · Sep 30, 2017 $104.68M
Cost Of Revenue Q3 2018 · Sep 30, 2018 $318K
Cost Of Revenue Q3 2018 · Sep 30, 2018 $708K
Cost Of Revenue Q3 2018 · Sep 30, 2017 $0
Cost Of Revenue Q3 2018 · Sep 30, 2017 $0
Capex restated Q3 2018 · Sep 30, 2017 $8.9M
Operating Cash Flow Q3 2018 · Sep 30, 2017 −$127.79M
Net Income restated Q3 2018 · Sep 30, 2017 −$65.01M
Net Income restated Q3 2018 · Sep 30, 2017 −$191.66M
Operating Income restated Q3 2018 · Sep 30, 2017 −$65.83M
Operating Income restated Q3 2018 · Sep 30, 2017 −$195.71M
Revenue Q3 2018 · Sep 30, 2017 $0
Revenue Q3 2018 · Sep 30, 2017 $0